AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16124967 — intervention group
Group type: COMPARATOR
Intervention: Technique 1 (thigh flexed and internally rotated throughout implantation of the femoral component)
Number of subjects: 19
Study 17876971 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency exercise (n = 8)
Number of subjects: 23
Study 17876971 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency exercise + group-based intervention (n = 8)
Number of subjects: 23
Study 17876971 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency exercise (control) (n = 7)
Number of subjects: 23
Study 10666547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin 100 microg/1 ml
Number of subjects: 12
Study 10666547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin 100 microg/20 microl
Number of subjects: 12
Study 10666547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin 100 microg/20 microl
Number of subjects: 12
Study 10666547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin 1 ml
Number of subjects: 12
Study 10666547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin 20 microl
Number of subjects: 12
Study 9463118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern and flash visual evoked potentials (VEP)
Number of subjects: 72
Study 9463118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ocular and neuroophthalmologic diseases)
Number of subjects: 72
Study 1730811 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate injections (3 mg/kg.week, im)
Number of subjects: 13
Study 6381461 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0
Study 6381461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30374945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nike Vaporfly (NVF)
Number of subjects: 24
Study 30374945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nike Vaporfly (NVF) matched in weight to ADI shoe (NVF+)
Number of subjects: 24
Study 30374945 — intervention group
Group type: COMPARATOR
Intervention: Nike Zoom Matumbo 3 (NZM)
Number of subjects: 24
Study 30374945 — intervention group
Group type: COMPARATOR
Intervention: Adidas Adizero Adios 3 (ADI)
Number of subjects: 24
Study 29771789 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg once daily (QD)
Number of subjects: 797
Study 29771789 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily (BID)
Number of subjects: 797
Study 29771789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 797
Study 27899103 — intervention group
Group type: EXPERIMENTAL
Intervention: TTE illustration (time-to-event format)
Number of subjects: 304
Study 27899103 — intervention group
Group type: COMPARATOR
Intervention: Emoticons (ten-year risk illustration)
Number of subjects: 304
Study 25239225 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m(2) once every 3 weeks (1/3 treatment arm)
Number of subjects: 52
Study 25239225 — intervention group
Group type: COMPARATOR
Intervention: Trabectedin 0.58 mg/m(2) every week for 3 of 4 weeks (3/4 treatment arm)
Number of subjects: 52
Study 23107042 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (3 g daily)
Number of subjects: 62
Study 23107042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20146700 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 0
Study 18408707 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) x 60 min
Number of subjects: 100
Study 18408707 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide (CP) x 30 min
Number of subjects: 100
Study 18408707 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) x 30 min with halogen activation
Number of subjects: 100
Study 18408707 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) x 30 min with diode laser activation
Number of subjects: 100
Study 18408707 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) x 30 min with plasma arc curing light
Number of subjects: 100
Study 18408707 — intervention group
Group type: COMPARATOR
Intervention: Control groups (matched)
Number of subjects: 100
Study 15838067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention designed to achieve and maintain a 7% weight loss and 150 minutes of exercise per week
Number of subjects: 1711
Study 15838067 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, 850 mg twice daily
Number of subjects: 1711
Study 15838067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1711
Study 15838067 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1711
Study 15838067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1711
Study 12456458 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO(2) = 1.0 (n = 10)
Number of subjects: 30
Study 12456458 — intervention group
Group type: EXPERIMENTAL
Intervention: VC maneuver + FIO(2) = 1.0 (n = 10)
Number of subjects: 30
Study 12456458 — intervention group
Group type: EXPERIMENTAL
Intervention: VC maneuver + FIO(2) = 0.4 (n = 10)
Number of subjects: 30
Study 10713806 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily gentamicin (4 mg/kg)
Number of subjects: 73
Study 10713806 — intervention group
Group type: COMPARATOR
Intervention: Twice daily gentamicin (2.5 mg/kg)
Number of subjects: 73
Study 7568637 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery during negatively valent conditions
Number of subjects: 48
Study 7568637 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery during high-arousal conditions
Number of subjects: 48
Study 7568637 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery during high-arousal imagery
Number of subjects: 48
Study 7568637 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery during low-arousal imagery
Number of subjects: 48
Study 7568637 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygomatic and corrugator activity
Number of subjects: 48
Study 29438649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol as an anticonvulsant drug
Number of subjects: 0
Study 29438649 — intervention group
Group type: COMPARATOR
Intervention: Cannabidiol
Number of subjects: 0
Study 27561153 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry-based culturally sensitive collaborative treatment (T-CSCT)
Number of subjects: 190
Study 27561153 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 190
Study 24910991 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout homogenates (BSH)
Number of subjects: 100
Study 24910991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alfalfa sprout homogenate)
Number of subjects: 100
Study 23227679 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupuncture therapy (4 weeks, 3-5 treatments per week)
Number of subjects: 73
Study 19560639 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 172
Study 19560639 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 172
Study 19560639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 172
Study 17233779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 1 hour before a meal and placebo 30-60 minutes before planned coitus
Number of subjects: 48
Study 17233779 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 hour before a meal and sildenafil 30-60 minutes before coitus
Number of subjects: 48
Study 17233779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil during a meal and placebo 30-60 minutes before coitus
Number of subjects: 48
Study 17233779 — intervention group
Group type: COMPARATOR
Intervention: Placebo during a meal and sildenafil 30-60 minutes before coitus
Number of subjects: 48
Study 15124981 — intervention group
Group type: EXPERIMENTAL
Intervention: R-roscovitine (50, 100, 200, 400, or 800 mg)
Number of subjects: 12
Study 15124981 — intervention group
Group type: EXPERIMENTAL
Intervention: R-roscovitine (50, 100, 200, 400, or 800 mg) after breakfast
Number of subjects: 12
Study 15124981 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxylate metabolite
Number of subjects: 12
Study 11773168 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin-based) followed by radical surgery (type III to V radical hysterectomy plus systematic pelvic lymphadenectomy)
Number of subjects: 441
Study 11773168 — intervention group
Group type: COMPARATOR
Intervention: External-beam radiotherapy (45 to 50 Gy) followed by brachyradiotherapy (20 to 30 Gy)
Number of subjects: 441
Study 9839764 — intervention group
Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 12
Study 9839764 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline in combination with donepezil (5 mg, once daily for 10 days)
Number of subjects: 12
Study 9839764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 12
Study 7807427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 62
Study 7807427 — intervention group
Group type: COMPARATOR
Intervention: No Sedation
Number of subjects: 62
Study 2510270 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 600 micrograms
Number of subjects: 182
Study 2510270 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 300 mg
Number of subjects: 182
Study 998148 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.1 mg/10 kg intravenously 2 min before induction)
Number of subjects: 0
Study 998148 — intervention group
Group type: COMPARATOR
Intervention: Halothane‐N2O/O2 anesthesia without atropine (control group)
Number of subjects: 0
Study 31272251 — intervention group
Group type: EXPERIMENTAL
Intervention: RTXM83
Number of subjects: 272
Study 31272251 — intervention group
Group type: COMPARATOR
Intervention: R-rituximab
Number of subjects: 272
Study 28069399 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 234
Study 28069399 — intervention group
Group type: COMPARATOR
Intervention: No stoma
Number of subjects: 234
Study 28069399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study 26008138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doxycycline 200, 100 and 100mg
Number of subjects: 24
Study 26008138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doxycycline 100, 50 and 50mg
Number of subjects: 24
Study 26008138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24094495 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of growth hormone (3mg/24h) for 60 hours
Number of subjects: 8
Study 21724796 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW program (meal replacements twice daily, intensive instruction in nutrition and meal preparation, exercise, and goal setting for three months)
Number of subjects: 89
Study 21724796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 89
Study 19792866 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy (ES/LC)
Number of subjects: 91
Study 19792866 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic bile duct exploration (LBDE) during laparoscopic cholecystectomy (LC)
Number of subjects: 91
Study 17072091 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg kg(‐1))
Number of subjects: 55
Study 17072091 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 55
Study 12967076 — intervention group
Group type: EXPERIMENTAL
Intervention: One Coat Bond (a 'one-bottle' system)
Number of subjects: 60
Study 12967076 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Up Bond F (an 'all-in-one' system)
Number of subjects: 60
Study 12967076 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 60
Study 10718946 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN (6 MU t.i.w.) plus ribavirin for 6 months
Number of subjects: 60
Study 10718946 — intervention group
Group type: COMPARATOR
Intervention: rIFN (6 MU t.i.w.) without ribavirin for 6 months
Number of subjects: 60
Study 8953321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for bulimia nervosa
Number of subjects: 0
Study 8953321 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0
Study 8953321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 0
Study 8953321 — intervention group
Group type: COMPARATOR
Intervention: Behavioral interventions and self-monitoring targeting body image
Number of subjects: 0
Study 1411629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 60 mg/m2 with 67.2 Gy radiation
Number of subjects: 36
Study 1411629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 50 mg/m2 with 67.2 Gy radiation
Number of subjects: 36
Study 1411629 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiotherapy (various carboplatin doses with radiation)
Number of subjects: 36
Study 1411629 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy (carboplatin/5-fluorouracil followed by conventional radiotherapy)
Number of subjects: 36
Study 3899673 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB JO28
Number of subjects: 20
Study 29247149 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ‐SC 162 mg q2w
Number of subjects: 656
Study 29247149 — intervention group
Group type: COMPARATOR
Intervention: Placebo-SC q2w
Number of subjects: 656
Study 27872513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) administration 4 hours before amniocentesis
Number of subjects: 111
Study 27872513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LF treatment)
Number of subjects: 111
Study 24958689 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (SDR) bulk fill technique
Number of subjects: 38
Study 24958689 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2 mm resin composite curing technique
Number of subjects: 38
Study 22809012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin mesilate 300 mg
Number of subjects: 40
Study 22809012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin mesilate 500 mg
Number of subjects: 40
Study 22809012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin mesilate 600 mg
Number of subjects: 40
Study 22809012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin mesilate 1,000 mg
Number of subjects: 40
Study 20484396 — intervention group
Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 351
Study 20484396 — intervention group
Group type: COMPARATOR
Intervention: Endovascular repair
Number of subjects: 351
Study 17583378 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease presence
Number of subjects: 499
Study 17583378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute symptoms upon arrival
Number of subjects: 499
Study 17583378 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for lacking medications
Number of subjects: 499
Study 17583378 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for presenting with acute symptoms
Number of subjects: 499
Study 15821120 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1200 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 397
Study 15821120 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 35 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 397
Study 11863237 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery distraction
Number of subjects: 41
Study 11863237 — intervention group
Group type: EXPERIMENTAL
Intervention: General distraction
Number of subjects: 41
Study 11863237 — intervention group
Group type: COMPARATOR
Intervention: No instruction
Number of subjects: 41
Study 9598837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fat diet
Number of subjects: 17
Study 9598837 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 17
Study 7895227 — intervention group
Group type: EXPERIMENTAL
Intervention: Human CNP (10 pmol.kg‐1.min‐1)
Number of subjects: 8
Study 7895227 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (6 ng.kg‐1.min‐1)
Number of subjects: 8
Study 7895227 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP
Number of subjects: 8
Study 7895227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2372338 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on land at 70% VO2max
Number of subjects: 7
Study 2372338 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in water at 70% VO2max
Number of subjects: 7
Study 2372338 — intervention group
Group type: COMPARATOR
Intervention: Comparison of land vs water exercise
Number of subjects: 7
Study 480622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 30
Study 480622 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 30
Study 31436705 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplement provided to pregnant and lactating mothers and their children
Number of subjects: 631
Study 31436705 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota maturity and diversity
Number of subjects: 631
Study 28941189 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vocational rehabilitation approach delivered by trained occupational therapists and physical therapists (1.5-hour meeting, action plan, written materials, telephone calls at 3 weeks and 3 months)
Number of subjects: 287
Study 28941189 — intervention group
Group type: COMPARATOR
Intervention: Control group received written materials only
Number of subjects: 287
Study 28798089 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (n=151)
Number of subjects: 307
Study 28798089 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (n=156)
Number of subjects: 307
Study 25727121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotonovela
Number of subjects: 132
Study 25727121 — intervention group
Group type: COMPARATOR
Intervention: Depression brochure
Number of subjects: 132
Study 23924586 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r 800/100 mg once daily (OD) monotherapy
Number of subjects: 30
Study 23924586 — intervention group
Group type: COMPARATOR
Intervention: DRV/r 800/100 mg OD plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 30
Study 23924586 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy
Number of subjects: 30
Study 23924586 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 30
Study 20625394 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar simulated radiation (SSR) at doses of 2 and 4 J/cm²
Number of subjects: 20
Study 20625394 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro luciferase assay
Number of subjects: 20
Study 19138933 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 45
Study 19138933 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 45
Study 19138933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19138933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondysplastic ACF
Number of subjects: 45
Study 19138933 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SMAD4 expression in ACF
Number of subjects: 45
Study 19138933 — intervention group
Group type: EXPERIMENTAL
Intervention: ACF histological examination
Number of subjects: 45
Study 19138933 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical comparison of ACF with adjacent normal mucosa
Number of subjects: 45
Study 16380297 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine plus folic acid
Number of subjects: 82
Study 16380297 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine alone
Number of subjects: 82
Study 16594274 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week pilot intervention based on Social Cognitive Theory
Number of subjects: 32
Study 16594274 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 32
Study 11189100 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (Cisplatin 100 mg/m2 on day 1 and fluorouracil 1000 mg/m2/day for 5 days, every 21 days) followed by loco-regional treatment.
Number of subjects: 318
Study 11189100 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy followed by loco-regional treatment.
Number of subjects: 318
Study 11189100 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (Cisplatin and fluorouracil) followed by loco-regional treatment.
Number of subjects: 318
Study 9373888 — intervention group
Group type: EXPERIMENTAL
Intervention: estropipate
Number of subjects: 38
Study 9373888 — intervention group
Group type: EXPERIMENTAL
Intervention: estropipate + nor-ethindrone
Number of subjects: 38
Study 9373888 — intervention group
Group type: COMPARATOR
Intervention: estrogen alone
Number of subjects: 38
Study 7504379 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed Mycobacterium leprae vaccine
Number of subjects: 147
Study 2990332 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper tissues treated with a combination of citric acid, malic acid, and sodium lauryl sulfate
Number of subjects: 18
Study 2990332 — intervention group
Group type: COMPARATOR
Intervention: Placebo tissues containing sodium saccharin
Number of subjects: 18
Study 31217024 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted radio advertising
Number of subjects: 1007
Study 31217024 — intervention group
Group type: EXPERIMENTAL
Intervention: Television news coverage
Number of subjects: 1007
Study 31217024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass mail-outs by a government health agency
Number of subjects: 1007
Study 31217024 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment promotions
Number of subjects: 1007
Study 31217024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-out by general practitioners (GPs)
Number of subjects: 1007